Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Neoadjuvant ipilimumab added to nivolumab improves outcomes in resectable advanced melanoma

ESMO 2024

13 - 17 Sep 2024

Published: 16 Sep 2024

Views: 16

Rating:

Save

Dr Minke W. Lucas - The Netherlands Cancer Institute, Amsterdam, Netherlands

Dr Lucas talks to ecancer at ESMO 2024 about data she presented from the phase 3 NADINA trial, looking at immunotherapy in resectable, macroscopic stage III melanoma.

The use of neoadjuvant ipilimumab plus nivolumab in resectable, macroscopic stage III melanoma resulted in improved distant metastasis-free survival and event free survival (EFS) as compared to adjuvant nivolumab.

This EFS-benefit was observed within stage IIIB- and IIIC melanoma.

Related Videos

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

ESMO 2024: Latest in bladder cancer - expert review

Dr Patrizia Giannatemp, Prof Andrea Necchi, Prof Simon Crabb, Dr Michiel Van...

ESMO 2024: Latest in bladder cancer - expert review ( Dr Patrizia Giannatemp, Prof Andrea Necchi, Prof Simon Crabb, Dr Michiel Van Der Heijden )

Bladder cancer updates from the first half of 2024

Prof Alison Birtle, Dr Ignacio Durán, Dr Patrizia Giannatempo

Bladder cancer updates from the first half of 2024 ( Prof Alison Birtle, Dr Ignacio Durán, Dr Patrizia Giannatempo )

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157...

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )

PD-1–refractory advanced melanoma: how do we get to the finish line?

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

$PD-1–refractory advanced melanoma: how do we get to the finish line? ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )$

Highlights in melanoma from ASCO 2024

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

Highlights in melanoma from ASCO 2024 ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )

Melanoma outcomes improved by dual immunotherapy before surgery rather than...

Prof Christian Blank - Netherlands Cancer Institute, Amsterdam, Netherlands

Melanoma outcomes improved by dual immunotherapy before surgery rather than after ( Prof Christian Blank - Netherlands Cancer Institute, Amsterdam, Netherlands )

Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma

Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany

Neoadjuvant daromun effective and safe for resectable, locally advanced melanoma ( Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany )

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal...

Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status ( Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain )

More from ecancer